Cabozantinib

The Formulary Management Expert Committee (FMEC) recommends that cabozantinib be reimbursed for adult patients with locally advanced or metastatic extrapancreatic or pancreatic neuroendocrine tumours who have received at least 1 prior therapy, provided certain conditions are met. Cabozantinib may be initiated in patients for the treatment of metastatic extrapancreatic or pancreatic neuroendocrine tumours if the following conditions are met: the tumour grade is consistent with WHO tumour grade 1 to 3; there is histological documentation of neuroendocrine tumour of pancreatic, gastrointestinal, lung, thymus, other, or unknown primary site; there is disease progression or unacceptable side effects after at least 1 prior therapy other than somatostatin analogue; and there is good performance status. A price reduction for cabozantinib may be required.